The latest news from academia, regulators
research labs and other things of interest
Posted: Jan 24, 2011
Nodality Takes Top Honors as 'Most Promising Company' at the Personalized Medicine World Conference 2011
(Nanowerk News) Silicom Ventures LLC, producer and co-host of the Personalized Medicine World Conference 2011 held January 18th and 19th, today announced that Nodality, Inc. was selected for the conference's "Most Promising Company" award. PMWC brings together the foremost leaders in personalized medicine from all aspects of business, government, healthcare-delivery and research to help accelerate the adoption of personalized medicine.
A total of twenty six companies participated in the award competition consisting of two rounds. In the first round, a screening panel evaluated each company's investor pitch and selected the top three for presentation to the conference's general assembly of over 800 attendees. In the final round, a panel of venture capitalists and industry representatives, as well as the audience, selected Nodality as the "Most Promising Company."
South San Francisco-based Nodality utilizes proprietary technology, Single Cell Network Profiling (SCNP), to characterize signaling pathways in cancer and autoimmune diseases. The SCNP platform will help increase the efficiency of drug R&D and allow the development of highly predictive diagnostics that can better link individual patients with appropriate therapies.
According to PMWC program chair, Amos Barzilay, "Nodality's approach is truly differentiated, with the ability of SCNP to go beyond sequence to function. Functional pathway analysis provides new insights into the biology of disease and thereby provides valuable information relevant to the clinical management of patients throughout their disease."
"In personalized medicine we're seeing promising new tools that improve patient treatment outcomes, as well as aid in the prevention and prediction of disease," said Rowan Chapman, Ph.D., PMWC Panel Judge and Mohr Davidow Partner. "In particular, single cell analysis at population scale is a potentially powerful tool for driving decision making in multiple disease areas. Nodality took the top prize in the PMWC competition because of the potential that its platform has to predict response to therapy and relapse risk in cancer patients."
"We are extremely honored to receive recognition as the Most Promising Company at this year's PMWC conference," stated David R. Parkinson, M.D. President and Chief Executive Officer of Nodality, Inc. "We look forward to fulfilling the role of the Most Promising Company as we execute on our strategy to use our proprietary technology to revolutionize the way patients are treated by matching individual patients to specific therapies based on the precise biology of their disease."
About Single Cell Network Profiling
Single Cell Network Profiling (SCNP) is a proprietary technology licensed from Stanford University to functionally characterize cell signaling networks in patients with cancer and autoimmune diseases. SCNP, a functional pathway analysis technology, has several advantages over other currently used molecular technologies. These include unprecedented insight into the presence and clinical meaning of cellular heterogeneity including the importance of rare cells such as drug-resistant and stem cells. As the technology has widespread application in both preclinical and clinical drug development, Nodality also is utilizing SCNP in collaboration with drug developers to decrease the time, cost, and risks of drug development.
Nodality develops and commercializes the next generation of personal diagnostic tests by characterizing cell signaling pathways in defined, cellular sub-populations of malignant and normal cells. The South San Francisco-based company applies proprietary, multiparametric Single Cell Network Profiling (SCNP) technology to develop highly predictive biological characterization tests to improve patient management in cancer and autoimmune diseases, the goal of personalized medicine. These tests will permit biologically informed clinical decisions of significant clinical utility.
Validation studies for tests to predict success of induction chemotherapy for acute myeloid leukemia (AML) are underway in collaboration with clinical investigators. In addition to the development of additional clinical tests for AML, SCNP also is being used in the development of new therapeutic agents for patients with other hematologic malignancies, autoimmune diseases, and solid tumors. For more information, please visit www.nodality.com.
About Silicom Ventures™
Silicom Ventures is the producer and co-host of the conference series, Personalized Medicine World Conference™. One of the largest private investment forums in the United States, Silicom Ventures has helped facilitate investment opportunities between investors and entrepreneurs in emerging technologies since 1999. For more information, please visit http://silicomventures.com.